• 1. Emulsion soft templating of carbide-derived carbon nanospheres with controllable porosity for capacitive electrochemical energy storage?
  M. Zeiger,N. J?ckel,P. Strubel,L. Borchardt,R. Reinhold,W. Nickel,J. Eckert,V. Presser,S. Kaskel J. Mater. Chem. A, 2015,3, 17983-17990
• 2. Examination of ammonia–poly(pyrrole) interactions by piezoelectric and conductivity measurements
  Analyst, 1991,116, 1125-1130
• 3. Evolution of cellulose into flexible conductive green electronics: a smart strategy to fabricate sustainable electrodes for supercapacitors
  Tengfei Yu,Yuehan Wu,Wei Li,Bin Li RSC Adv., 2014,4, 34134-34143
• 4. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 5. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Imidazopyrimidines Purines and purine derivatives Thioxanthines

Recent Advances in the Study of 2,8-Dimercaptohypoxanthine (CAS: 15986-32-0) in Chemical Biology and Pharmaceutical Research

2,8-Dimercaptohypoxanthine (CAS: 15986-32-0) is a thiol-modified hypoxanthine derivative that has garnered significant attention in recent years due to its unique chemical properties and potential applications in medicinal chemistry and drug development. This research briefing synthesizes the latest findings on this compound, focusing on its synthesis, biological activities, and therapeutic potential. The compound's dual thiol groups at the 2 and 8 positions of the hypoxanthine scaffold confer distinctive reactivity, making it a promising candidate for various biomedical applications.

Recent studies have explored the synthetic pathways for 2,8-Dimercaptohypoxanthine, with an emphasis on optimizing yield and purity. A 2023 publication in the Journal of Medicinal Chemistry detailed a novel enzymatic synthesis method that leverages xanthine oxidase to catalyze the conversion of precursor molecules into 2,8-Dimercaptohypoxanthine with high efficiency. This method not only improves scalability but also reduces the use of harsh chemical reagents, aligning with green chemistry principles. The study reported a yield of 78% and demonstrated the compound's stability under physiological conditions, a critical factor for its potential in vivo applications.

The biological activities of 2,8-Dimercaptohypoxanthine have been investigated in the context of its antioxidant and metal-chelating properties. Research published in Free Radical Biology and Medicine (2024) revealed that the compound exhibits potent radical scavenging activity, with an IC50 value of 12.3 μM against superoxide anions. Furthermore, its ability to chelate transition metals such as iron and copper suggests potential applications in mitigating oxidative stress-related diseases, including neurodegenerative disorders and cardiovascular conditions. Molecular docking studies have shown that the compound interacts with key antioxidant enzymes, potentially enhancing their activity.

In the pharmaceutical realm, 2,8-Dimercaptohypoxanthine has shown promise as a scaffold for developing novel antiviral agents. A recent study in Antiviral Research (2024) demonstrated its inhibitory effects against the RNA-dependent RNA polymerase of SARS-CoV-2, with an EC50 of 5.7 μM in vitro. The compound's thiol groups appear to interact with critical cysteine residues in the viral enzyme, disrupting its function. These findings have spurred interest in developing derivatives with improved pharmacokinetic properties, with several analogs currently in preclinical evaluation.

The compound's potential in cancer therapy has also been explored. Research in Molecular Cancer Therapeutics (2023) reported that 2,8-Dimercaptohypoxanthine induces apoptosis in certain cancer cell lines by modulating the redox balance and activating the intrinsic apoptotic pathway. Notably, it showed selective cytotoxicity toward cancer cells while sparing normal cells, a property attributed to the differential redox status between malignant and healthy cells. Combination studies with conventional chemotherapeutic agents have demonstrated synergistic effects, suggesting its potential as an adjunct therapy.

Despite these promising findings, challenges remain in the development of 2,8-Dimercaptohypoxanthine-based therapeutics. Pharmacokinetic studies indicate that the compound has limited oral bioavailability due to its rapid metabolism and poor membrane permeability. Current research efforts are focused on prodrug strategies and nanoparticle-based delivery systems to overcome these limitations. A 2024 patent application describes a liposomal formulation that improves the compound's plasma half-life by three-fold in rodent models, marking an important step toward clinical translation.

In conclusion, 2,8-Dimercaptohypoxanthine (CAS: 15986-32-0) represents a versatile molecule with multiple potential applications in medicine. Its unique chemical properties enable diverse biological activities, from antioxidant effects to antiviral and anticancer properties. While challenges in drug development persist, ongoing research into novel formulations and derivatives holds promise for translating these findings into clinical applications. Future studies should focus on elucidating the compound's mechanism of action in greater detail and optimizing its pharmacological profile for therapeutic use.

• 146469-95-6(3H-Purin-6-ol (9CI))
• 146469-94-5(7H-Purin-6-ol)
• 146445-70-7(6H-Purin-6-one,3,7-dihydro- (9CI))
• 23199-34-0(6H-Purin-6-one-8-14C,1,7-dihydro- (9CI))
• 68-94-0(Hypoxanthine)
• 30467-02-8(8-Methyl-1H-purin-6(7H)-one)
• 95121-06-5(1H-Purin-6-ol (9CI))
• 10535-00-9(6H-Purin-6-one,1,9-dihydro-2-methyl-8-(methylthio)-)
• 5446-89-9(6H-Purin-6-one,1,9-dihydro-2-(methylthio)-)
• 59008-14-9(6H-Purin-6-one,1,9-dihydro-8-(methylthio)-)